NIH study identifies new molecules involved in diabetes.
Cambridge scientists have successfully trialled an artificial pancreas for use by patients living with type 2 diabetes. The device – powered by an algorithm developed at the University of Cambridge – doubled the amount of time patients were in the target range for glucose compared to standard treatment and halved the time spent experiencing high glucose levels.
Research reveals how the drugs target an enzyme involved in lowering blood sugar.
A new study identified microbial signatures which predicted the onset of type 2 diabetes during nearly 16 years of follow-up in a large Finnish population cohort. This study was conducted by researchers from the University of Turku and Finnish Institute of Health and Welfare (THL), together with international partners.
Scientists at the University of Cambridge have identified rare genetic variants – carried by one in 3,000 people – that have a larger impact on the risk of developing type 2 diabetes than any previously identified genetic effect.
A clinical study has investigated whether immunotherapy against type 1 diabetes can preserve the body’s own production of insulin. The results suggest that injection of a protein, GAD, into lymph nodes can be effective in a subgroup of individuals.